Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.

Adult Antitubercular Agents / administration & dosage Arylamine N-Acetyltransferase / genetics Cytochrome P-450 Enzyme System / genetics Drug Administration Schedule Drug Therapy, Combination Drug-Related Side Effects and Adverse Reactions Female Humans Isoniazid / administration & dosage Latent Tuberculosis / drug therapy Male Odds Ratio Polymorphism, Single Nucleotide Rifampin / administration & dosage
adverse drug reaction drug metabolic enzymes latent tuberculosis polymorphism

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
27 12 2019
Historique:
received: 11 11 2019
revised: 24 12 2019
accepted: 25 12 2019
entrez: 2 1 2020
pubmed: 2 1 2020
medline: 9 6 2020
Statut: epublish

Résumé

Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015-4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022-2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250-2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.

Identifiants

DOI: 10.3390/ijerph17010210 PMID: 31892222 PMC: PMC6981901
pubmed: 31892222
pii: ijerph17010210
doi: 10.3390/ijerph17010210
pmc: PMC6981901
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Cytochrome P-450 Enzyme System 9035-51-2
Arylamine N-Acetyltransferase EC 2.3.1.5
NAT2 protein, human EC 2.3.1.5
Isoniazid V83O1VOZ8L
Rifampin VJT6J7R4TR
rifapentine XJM390A33U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Infect Dis. 2015 Aug 15;61(4):527-35
pubmed: 25904367
Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43
pubmed: 25489785
Medicine (Baltimore). 2016 Aug;95(34):e4126
pubmed: 27559940
Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7
pubmed: 12531776
Drug Metab Rev. 2015 May;47(2):222-8
pubmed: 26095714
Curr Med Res Opin. 2013 Jan;29(1):1-12
pubmed: 23136913
Drug Metab Pharmacokinet. 2002;17(4):357-62
pubmed: 15618686
In Vivo. 2011 Sep-Oct;25(5):803-12
pubmed: 21753138
Clin Infect Dis. 2018 Jul 2;67(2):193-201
pubmed: 29415190
Genome Med. 2013 Jan 29;5(1):5
pubmed: 23360680
N Engl J Med. 2011 Dec 8;365(23):2155-66
pubmed: 22150035
Nat Rev Drug Discov. 2007 Nov;6(11):904-16
pubmed: 17971785
Curr Top Med Chem. 2004;4(13):1411-21
pubmed: 15379654
Clin Infect Dis. 2015 Oct 15;61(8):1322-7
pubmed: 26082504
J Antimicrob Chemother. 2019 Jan 1;74(1):218-227
pubmed: 30295760
Antimicrob Agents Chemother. 2001 Feb;45(2):382-92
pubmed: 11158730
Am J Health Syst Pharm. 2000 May 1;57(9):887-98; quiz 899-901
pubmed: 10840530
J Clin Med. 2019 Feb 26;8(3):null
pubmed: 30813594
Am J Respir Crit Care Med. 2015 Feb 1;191(3):251-2
pubmed: 25635488
J Antimicrob Chemother. 2014 Apr;69(4):1079-85
pubmed: 24343893
Nature. 2015 Oct 15;526(7573):343-50
pubmed: 26469045
Eur J Clin Pharmacol. 2002 Jan;57(11):799-804
pubmed: 11868802
Acta Pharm Sin B. 2016 Sep;6(5):384-392
pubmed: 27709007
Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v
pubmed: 26260821
Int J Infect Dis. 2015 Apr;33:28-31
pubmed: 25271170
Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9
pubmed: 24060875
Antimicrob Agents Chemother. 1999 Dec;43(12):2922-4
pubmed: 10582883
Drug Saf. 2002;25(8):553-60
pubmed: 12113641
JAMA. 1999 Aug 18;282(7):677-86
pubmed: 10517722
MMWR Morb Mortal Wkly Rep. 2011 Dec 9;60(48):1650-3
pubmed: 22157884
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526-30
pubmed: 12045127

Auteurs

Ya-Yen Yu (YY)

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Department of Clinical Laboratory, Changhua Hospital, Changhua 513, Taiwan.

Shih-Ming Tsao (SM)

Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan.

Wen-Ta Yang (WT)

Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan.

Wei-Chang Huang (WC)

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan.
Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan.
Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 407, Taiwan.
ORCID: 0000-0002-9733-5899

Ching-Hsiung Lin (CH)

Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan.

Wei-Wen Chen (WW)

Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.

Shun-Fa Yang (SF)

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
ORCID: 0000-0002-0365-7927

Hui-Ling Chiou (HL)

School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan.
Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

Yi-Wen Huang (YW)

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.
ORCID: 0000-0001-6097-3910

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Acyltransferases › Acetyltransferases › Arylamine N-acetyltransferase › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Calendrier d'administration des médicaments › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides isonicotiniques › Isoniazide › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Infection › Infection latente › Tuberculose latente › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Odds ratio › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Association of Drug Metabolic Enzyme Genetic...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Association of Drug Metabolic Enzyme Genetic...